Foley Hoag represented LigaChem Biosciences (LCB), a clinical-stage biotech company, in multiple transactions involving the development of antibody-drug conjugates (ADCs) closing in the second week of September.
The first transaction was a worldwide in-licensing transaction with Go Therapeutics for a new antibody platform designed for the development of ADCs. LCB secured global rights to develop and commercialize ADCs based on Go Therapeutics’ antibody technology. Foley Hoag attorneys Sarah Cooleybeck, Sumi Sedor and Ivanna Bihun represented LCB in this transaction, with intellectual property assistance from Maya Elbert.
The second transaction was with Trican Biotechnology for an antibody discovery agreement, in which LCB will advance its proprietary pipeline of ADCs using antibodies generated by Trican Biotechnology. Foley Hoag attorneys John Harre and Ivanna Bihun represented LCB in this transaction.